Pharmacokinetics and Safety Study of Apetrol ES

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

A Randomized, Open Label, Single dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of Apetrol ES and Megace® in Healthy Male Volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: LG Life Sciences
• Collaborator: Severance Hospital
• Treatments: Megestrol; Megestrol Acetate

Criteria

Inclusion Criteria:

• Is a healty male between 20 and 55 years old.

• In a ± 20% than ideal body weight. [ideal body weight(kg) = height(cm)-100) x 0.9 (Broca's rule)

• Subjects who are considered to be suitable in conducting the clinical trial in serum test, hematology test, hemato-chemical test, urine test and 12-ECG result.

• Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

• Agrees to use an adequate means of contraception during clinical trials

• Subject who has voluntarily decided to participate in this clinical trial and consented in writing.

Exclusion Criteria:

• Is allergic against Megestrol acetate or other drugs (Aspirin, NSAIDs, Antibiotics, etc.) or against foods, or has an clinically serious allergic history.

• Subjects who have present condition or past history of any disease involving liver, kidney, nervous system, immune system, respiratory system, or endocrine system; hematologic and oncologic disease; cardiovascular disease; or psychiatric disorder (mood disorder, obsessive-compulsive disorder, etc. that may affect ADME of investigational medicinal products.

• In the vital signs measured in sitting position at the screening visit, subjects who have hypertension desease(a systolic blood pressure of ≥ 150 mmHg or a diastolic blood pressure of ≥ 100 mmHg).

• Diabetic patients or the patients who are abnormal of impaired glucose tolerance.

• The patients who have a history of Arterial Embolism.

• The patients who have a history of adrenal insufficiency like hypotension or nausea or vertigo or asthenia or etc.

• Subjects who have a history of drug abuse or shown positive reaction to drugs that may be abused from a urine drug screening

• Subjects who took any specialized drug or an herbal medication within 2 weeks before the date of first administration or took any over the counter (OTC) drug within 1 week (however, they may be included as subjects if appropriate depending on the investigator's discretion)

• Subjects who had whole blood donation within 2 months or component blood donation within 1 month before the clinical trial.

• Subjects who have abnormal diets that may affect ADME of investigational medicinal products.

• Subjects who have been drinking extremely alcohol and caffeine (more than caffeine 5 cups/day, soju 3 cups/day, beer 3 cups/day, liquors 2 cups/day, 10 cigarettes/day) or can't refrain from drinking during the clinical trial period.

• Subjects who had administration a barbiturates within 1 month before the date of first drug administration

• Subjects who already participated in other clinical trials within 2 months before this clinical trial.

• Subjects who are considered to be unsuitable in conducting the clinical trial for other reason at the principal investigator's discretionary judgment